Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM).

Full DD Report for RYTM

You must become a subscriber to view this report.


Recent News from (NASDAQ: RYTM)

Rhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference
BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that company management will present a c...
Source: GlobeNewswire
Date: November, 07 2018 08:00
Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CURO Group Holdings Corp. (NYSE:CURO), BiondVax Pharmaceuticals Ltd. (NAS...
Source: GlobeNewswire
Date: October, 17 2018 08:15
Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer
BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the appointment of Murray W. Stewart, D....
Source: GlobeNewswire
Date: October, 15 2018 08:00
Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
BOSTON, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-interventional ...
Source: GlobeNewswire
Date: September, 28 2018 07:00
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting
BOSTON, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that updated data from the company ...
Source: GlobeNewswire
Date: September, 28 2018 07:00
Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference
BOSTON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Ex...
Source: GlobeNewswire
Date: September, 25 2018 08:00
Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference
BOSTON, Sept. 07, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Ex...
Source: GlobeNewswire
Date: September, 07 2018 08:00
New Research: Key Drivers of Growth for Harmonic, Astec Industries, Marlin Business Services, Arsanis, SunOpta, and Rhythm Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Harmonic Inc. (NASDAQ:HLIT), Astec Industries, Inc. (NASDAQ:ASTE), Marlin...
Source: GlobeNewswire
Date: August, 20 2018 07:55
Rhythm Pharmaceuticals reports Q2 results
Rhythm Pharmaceuticals (NASDAQ: RYTM ): Q2 EPS of -$0.52 More news on: Rhythm Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 08 2018 16:50
Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results
-- Completed Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Pro-opiomelanocortin (POMC) and Leptin Receptor (LEPR) Deficiency Obesity -- -- Announced New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare G...
Source: GlobeNewswire
Date: August, 08 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0830.7630.8731.2029.02112,694
2018-05-1730.3931.8833.1630.12146,974

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1412,23517,43470.1790Short
2018-12-1326,34534,22776.9714Short
2018-12-1213,80423,35359.1102Short
2018-12-1114,09819,41772.6065Short
2018-12-108,15110,85075.1244Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RYTM.


About Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)

Logo for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: RYTM)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 14 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 12 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: February, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: RYTM)

      Daily Technical Chart for (NASDAQ: RYTM)


      Stay tuned for daily updates and more on (NASDAQ: RYTM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: RYTM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RYTM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RYTM and does not buy, sell, or trade any shares of RYTM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/